Key result
This review outlines the clinical approach to patients with hypertrophic cardiomyopathy, focusing specifically on those presenting with the clinical syndrome of heart failure.
This review provides an updated approach to the management of patients with hypertrophic cardiomyopathy, with a specific focus on those presenting with heart failure.
Answers are grounded in this paper and cite their sources.
Provides synthesized guidance for HCM-HF management; extends prior reviews as Level 5 evidence while leaving key questions open.
Hypertrophic cardiomyopathy (HCM) is a global disease with cases reported in all continents, affecting people of both genders and of various racial and ethnic origins. Widely accepted as a monogenic disease caused by a mutation in 1 of 13 or more sarcomeric genes, HCM can present catastrophically with sudden cardiac death (SCD) or ventricular arrhythmias or insidiously with symptoms of heart failure. Given the velocity of progress in both the fields of heart failure and HCM, we present a review of the approach to patients with HCM, with particular attention to those with HCM and the clinical syndrome of heart failure.
No takes yet. Share an insight, caveat, or question.
Houston et al. (2014) conducted a review in Hypertrophic cardiomyopathy (HCM). This review outlines the clinical approach to patients with hypertrophic cardiomyopathy, focusing specifically on those presenting with the clinical syndrome of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: